Real-World study tracks tucatinib combo for tough breast cancer
NCT ID NCT05253911
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at how well the drug tucatinib (Tukysa) works in everyday medical practice for people with advanced HER2-positive breast cancer who had already tried at least two other treatments. Researchers tracked 49 adults in Germany and Austria to see how their quality of life changed and how long it took for their cancer to worsen. The goal was to understand the real-world benefits of adding tucatinib to standard therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medizinische Universität Wien, Innere Medizin I, Hämatologie und Onkologie
Vienna, 1090, Austria
-
Universitätsklinikum Essen, Innere Klinik (Tumorforschung)
Essen, North Rhine-Westphalia, D-45112, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
- Can a new drug outsmart resistant breast cancer?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?